8-K: Clearside Biomedical Files Chapter 11, Nasdaq Delisting

Clearside Biomedical has filed for Chapter 11 bankruptcy and faces delisting from Nasdaq, aiming to sell its assets.

Summary

• Clearside Biomedical, Inc. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on November 23, 2025, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 25-12109).
• The company will operate as a debtor-in-possession with the objective to consummate a sale of substantially all of its assets to the highest bidder.
• On November 24, 2025, the company received a Delisting Notice from Nasdaq, stating its common stock will be delisted due to the Chapter 11 filing and prior non-compliance with the $50,000,000 minimum Market Value of Listed Securities requirement (notice received August 28, 2025).
• Trading of the common stock on Nasdaq will be suspended at the opening of business on December 1, 2025.
• The company does not intend to appeal Nasdaq's delisting determination, and the common stock is expected to begin trading exclusively on the over-the-counter (OTC) market under the symbol CLSDQ on December 1, 2025.
• The company issued a press release on November 24, 2025, announcing the Chapter 11 filing and its intent to pursue a strategic sale of its business through an auction process under Section 363 of the U.S. Bankruptcy Code.
• Key assets highlighted for sale include the SCS Microinjector delivery platform, the commercial product XIPERE, five suprachoroidal licensing collaborations with future royalty revenue potential, the CLS-AX TKI program (Phase 3-ready in wet AMD and a path for Phase 2b/3 in diabetic retinopathy), and IND-ready programs targeting Geographic Atrophy and Diabetic Macula Edema.
• Advisors for the process include Cooley LLP and Richards, Layton & Finger, P.A. as legal counsel, and Berkeley Research Group LLC (BRG) as financial restructuring advisor.

Sentiment

Score: 1

Explanation: The filing announces Chapter 11 bankruptcy, delisting from Nasdaq, and the intent to sell substantially all company assets, which are extremely negative events for shareholders and indicate severe financial distress.

Positives

• Possesses a validated SCS Microinjector delivery platform, including commercial scale manufacturing capability with ISO and CE mark certification.
• Successfully navigated the U.S. Food & Drug Administration (FDA) regulatory pathway to obtain commercial approval for XIPERE (triamcinolone acetonide injectable suspension) for uveitic macular edema.
• A permanent CPT code is assigned in the United States for suprachoroidal injections, potentially enabling physicians to receive higher reimbursement.
• The CLS-AX (axitinib injectable suspension) program includes a Phase 3-ready asset in wet AMD and a path for a Phase 2b/3 trial in diabetic retinopathy, with positive Phase 1/2a and Phase 2b wet AMD clinical trial data.
• Has IND-ready preclinical small molecule programs targeting Geographic Atrophy and Diabetic Macula Edema.
• Maintains five suprachoroidal licensing collaborations with companies such as Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, REGENXBIO (and AbbVie), and Arctic Vision (and Santen), offering future royalty revenue potential.
• Equity in Clearside Royalty LLC and the right to revenue from royalties after reaching the $106.5 million cap purchased by HCR are available assets for sale.

Negatives

• Filed for voluntary Chapter 11 bankruptcy protection.
• Received notice of delisting from The Nasdaq Stock Market LLC.
• Common stock will be suspended from trading on Nasdaq on December 1, 2025.
• Common stock will transfer to the over-the-counter (OTC) market under the symbol CLSDQ.
• Previously failed to satisfy Nasdaq's minimum Market Value of Listed Securities of $50,000,000.
• The company's objective is to sell substantially all of its assets, indicating a cessation of independent operations.

Risks

• Uncertainty regarding the court's approval of Clearside's first-day motions.
• Risks and uncertainties regarding Clearside's ability to successfully consummate and complete a plan of reorganization under Chapter 11.
• Potential adverse impact of the bankruptcy proceedings on Clearside's business, financial condition, liquidity, and results of operations.
• Clearside's ability to maintain contracts that are critical to expected limited operations and meet financial obligations during the bankruptcy proceedings.
• Uncertainty regarding the outcome and timing of the bankruptcy process and any potential sale of all or some of Clearside's assets.
• The effect of the filing of bankruptcy and any potential sale of all or some of Clearside's assets on its relationships with third parties.
• Clearside's expectations regarding liquidity and obligations, including its use of, and need for, cash and any other underlying assumptions.
• The length of time that Clearside will operate under Chapter 11 and the continued availability of operating capital during such pendency.
• The impact of the Chapter 11 case on the trading price and volatility of Clearside's common stock and the possible delisting of Clearside's common stock.
• Any potential proceedings that may be brought by third parties in connection with the bankruptcy petitions or the potential sale of all or some of Clearside's assets.
• Uncertainty regarding obtaining the bankruptcy court's approval of the potential sale of all or some of Clearside's assets or other terms and conditions to any such potential sale.
• Clearside's ability to negotiate and obtain any financing, including debtor in possession funding, with lenders or creditors during the Chapter 11 case and to comply with the restrictions imposed by the terms and conditions of the potential financing arrangements, if any.
• The timing or amount of any distributions, if any, to Clearside's stakeholders.
• Clearside's ability to retain senior management and other key personnel during the pendency of the Chapter 11 case.
• Uncertainties inherent in the conduct of clinical trials, Clearside's reliance on third parties over which it may not always have full control, and Clearside's ability to raise additional capital.

Future Outlook

The company's primary objective is to consummate a sale of substantially all of its assets to the highest bidder through an auction process under Section 363 of the U.S. Bankruptcy Code. Management believes this structured process represents the best possible option for stakeholders, aiming to maximize value from its SCS Microinjector platform, CLS-AX program, licensing agreements, and other related assets.

Management Comments

• "Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders." George Lasezkay, PharmD, JD, President and Chief Executive Officer.
• "We believe that we have attractive assets based on our clinically proven SCS Microinjector platform and associated intellectual property, our successful suprachoroidal CLS-AX (axitinib injectable suspension) clinical development program, multiple suprachoroidal licensing agreements and other related assets." George Lasezkay, PharmD, JD, President and Chief Executive Officer.

Industry Context

The biopharmaceutical industry, particularly in ophthalmology, is highly capital-intensive and competitive. Clearside's bankruptcy filing highlights the significant challenges smaller biotech companies face in bringing innovative therapies to market, even with promising clinical assets and a validated delivery platform. The strategic sale of assets suggests a trend where valuable intellectual property and development programs from distressed companies are acquired by larger players, rather than the independent commercialization by the original developer. The focus on suprachoroidal delivery and TKI programs for wet AMD and diabetic retinopathy remains a key area of innovation in eye care.

Comparison to Industry Standards

• The company's failure to meet Nasdaq's minimum Market Value of Listed Securities of $50,000,000 indicates underperformance relative to typical public company listing standards.
• The move to Chapter 11 bankruptcy and an asset sale is a severe outcome, contrasting sharply with successful biopharmaceutical companies that secure sufficient funding to advance their pipelines through late-stage clinical trials and commercialization.
• While the SCS Microinjector platform and CLS-AX program show promise, the inability to independently finance their development to market suggests a failure to meet the capital-raising benchmarks common for companies with Phase 3-ready assets.
• The existing licensing agreements with companies like Bausch + Lomb, REGENXBIO (and AbbVie), and Arctic Vision (and Santen) demonstrate that the underlying technology has garnered industry validation, but Clearside's financial position prevented it from fully capitalizing on these partnerships or its internal pipeline.

Legal Proceedings

• Voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 25-12109) filed in the United States Bankruptcy Court for the District of Delaware.
• Motions seeking 'first-day relief' have been filed with the Court.
• Intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.

Stakeholder Impact

• Shareholders: Significant negative impact due to delisting, transfer to the OTC market, and the high likelihood of substantial or complete loss of investment given the Chapter 11 filing and asset sale.
• Employees: Uncertainty regarding job security and future employment as the company liquidates assets.
• Creditors: Subject to the bankruptcy process, with potential for partial or no recovery depending on the asset sale outcome and priority of claims.
• Customers/Partners: Existing licensing partners (e.g., Bausch + Lomb, REGENXBIO) may see their agreements transferred or renegotiated as part of the asset sale, potentially impacting their ongoing programs.

Next Steps

• Continue operating as a debtor-in-possession under the jurisdiction of the U.S. Bankruptcy Court for the District of Delaware.
• File motions seeking 'first-day relief' to ensure the continuation of normal operations during the bankruptcy process.
• Pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code to sell substantially all assets to the highest bidder.
• Interested parties are required to submit binding offers to acquire Clearside's assets in whole or in part.
• The common stock will begin trading exclusively on the over-the-counter (OTC) market under the symbol CLSDQ on December 1, 2025.

Key Dates

Recommendation

The company has filed for Chapter 11 bankruptcy, will be delisted from Nasdaq, and intends to sell substantially all of its assets. This indicates severe financial distress and likely liquidation, which typically results in a near-total loss for equity holders. The stock will move to the illiquid OTC market, further reducing any potential recovery.

Keywords

Clearside Biomedical, CLSD, CLSDQ, Chapter 11, Bankruptcy, Nasdaq Delisting, Asset Sale, SCS Microinjector, XIPERE, CLS-AX, Wet AMD, Diabetic Retinopathy, Suprachoroidal Space, Biopharmaceutical, Ophthalmic, Eye Disease, TKI, FDA, Epiq Bankruptcy Solutions